Baton Rouge, LANCT07145229Now EnrollingIRB Ready

Gout Clinical Trial in Baton Rouge, LA

Access cutting-edge gout treatment through this phase 2 clinical trial at a research site in Baton Rouge. Study-provided care at no cost to qualified participants.

Sponsored by Atom Therapeutics Co., Ltd

Quick Self-Assessment

See if you qualify for this Baton Rouge location

Preparing your pre-screening questions…

Expert Care in Baton Rouge

Access gout specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gout treatment provided free

Apply for This Baton Rouge Location

Check if you qualify for this gout clinical trial in Baton Rouge, LA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Baton Rouge

    Convenient for LA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Baton Rouge site if eligible
  4. 4Begin participation

About This Gout Study in Baton Rouge

A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.

Sponsor: Atom Therapeutics Co., Ltd

Who Can Participate

Inclusion Criteria

Subjects are eligible for the study if they meet all of the following Inclusion Criteria:
Age 18-70 years old (inclusive), male or female.
Body mass index (BMI)18-40 kg/m2 (inclusive).
Medical history and current findings consistent with diagnosis of gouty arthritis.
Subjects must have experienced 2 or more gout flares within 12 months prior to screening.
Onset of an acute gout flare, within 6 months
Patients receiving ULT agents (such as allopurinol, febuxostat, probenecid, etc.) must be on stable doses of these drugs prior to first dose of study drug (and remain on the same dose throughout the Treatment Period).
Subjects agree to maintain a stable lifestyle (such as diet and exercise) during the study period. Key

Exclusion Criteria

Subjects are excluded from the study if one or more of the following criteria are met:
Administration of oral prednisone ≥ 10 mg or equivalent doses of other glucocorticoids, or use of narcotics, within 24 hours prior to first dose of study drug, or intramuscular, intravenous, or intra-articular injection of any glucocorticoid within 14 days prior to first dose of study drug.
Use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) prior to first dose dose of study drug, at the investigator's discretion.
Administration of colchicine or ABP-745 within 14 days prior to first dose of study drug.
Subjects took any investigational drug in any clinical study within 1 month prior to first dose of study drug and throughout the study period.
Administration of pegloticase, or methotrexate, or any biologic IL-1 blocker, TNF inhibitor, or other biological agent within 30 days prior to first dose of study drug or within 5 half-lives of the study drug prior to the first dose of study drug, whichever is longer.
Administration of muscle relaxants, central stimulants, barbiturates, etc. within 30 days prior to first dose of study drug or within 5 half-lives of the drug prior to the first dose of study drug, whichever is longer.
Secondary gout (e.g., gout induced by chemotherapy, transplant-related gout).
Subjects with a current diagnosis or history of rheumatoid arthritis, psoriatic arthritis, evidence or suspicion of infectious/septic arthritis, calcium pyrophosphate (CPP) crystal arthritis, acute polyarticular gout (4 or more joints), multiple sclerosis or any other demyelinating disease, or; major chronic inflammatory disease or connective tissue disease other than RA or psoriatic arthritis (PsA), including but not limited to fibromyalgia or systemic lupus erythematosus (with the exception of secondary Sjögrens syndrome, etc.); with arthritis due to any cause other than gout that may confound any study assessments per Investigator discretion or Prosthetic joint infection within 5 years of screening, or native joint infection within 1 year of screening
Current anticoagulation therapy, thrombocytopenia, or diseases with a risk of thrombocytopenia, such as aplastic anemia, hypersplenism, or known hemorrhagic diseases like idiopathic thrombocytopenic purpura or hemophilia.
History of malignancy within 5 years prior to screening, excluding localized cancers such as basal cell carcinoma.
Presence of significant diseases, including but not limited to: uncontrolled hypertension (systolic blood pressure ≥160 or diastolic blood pressure ≥100 mmHg), congestive heart failure (New York Heart Association \[NYHA\] class III or above), uncontrolled type 1 or 2 diabetes mellitus (hemoglobin A1c \[HbA1c\] \>8.5%). Inclusion will be determined by the Investigator based on the subject's specific condition.
Women of childbearing potential as defined by Appendix 2.
Experienced only no or mild gout-related pain prior to first dose of study drug.
Use of gout flare prophylaxis (e.g., colchicine, NSAIDs, prednisone/methylprednisolone) at the time of randomization based on conversation with subject and self-reported.
Corona Virus Disease (COVID) vaccination in the 4 weeks prior to randomization.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Baton Rouge?

Yes, this clinical trial (NCT07145229) has an active research site in Baton Rouge, LA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gout Treatment Options in Baton Rouge, LA

If you're searching for gout treatment options in Baton Rouge, LA, this clinical trial (NCT07145229) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Baton Rouge research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced gout specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gout clinical trials near you to find additional studies recruiting in your area.

More Gout Trials in Baton Rouge, LA

See all gout clinical trials recruiting in Baton Rouge — not just this study.

Browse Gout Trials in Baton Rouge →

Browse More Trials by Condition

Gout TrialsAll Conditions →

Ready to Join in Baton Rouge?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Baton Rouge, LA